KATs Off: Biomedical Insights from Lysine Acetyltransferase Inhibitors

Overview

Journal Curr Opin Chem Biol

Publisher Elsevier

Specialty Biochemistry

Date 2022 Dec 30

PMID 36584580

Authors

Samuel D Whedon

Philip A Cole

Affiliations

Soon will be listed here.

Abstract

Lysine acetyltransferase (KAT) enzymes including the p300, MYST, and GCN5 families play major roles in modulating the structure of chromatin and regulating transcription. Because of their dysregulation in various disease states including cancer, efforts to develop inhibitors of KATs have steadily gained momentum. Here we provide an overview of recent progress on the development of high quality chemical probes of the p300 and MYST family of KATs and how they are emerging as useful tools for basic and translational investigation.

Citing Articles

Targeting lysine acetylation readers and writers.

Zhou M, Cole P Nat Rev Drug Discov. 2024; 24(2):112-133.

PMID: 39572658 PMC: 11798720. DOI: 10.1038/s41573-024-01080-6.

Paralogue-Selective Degradation of the Lysine Acetyltransferase EP300.

Chen X, Crawford M, Xiong Y, Shaik A, Suazo K, Bauer L JACS Au. 2024; 4(8):3094-3103.

PMID: 39211607 PMC: 11350577. DOI: 10.1021/jacsau.4c00442.

Evaluating the Cellular Roles of the Lysine Acetyltransferase Tip60 in Cancer: A Multi-Action Molecular Target for Precision Oncology.

Zohourian N, Coll E, Dever M, Sheahan A, Burns-Lane P, Brown J Cancers (Basel). 2024; 16(15).

PMID: 39123405 PMC: 11312108. DOI: 10.3390/cancers16152677.

The role of acetylation in obesity-induced cardiac metabolic alterations.

Ketema E, Lopaschuk G J Pharm Pharm Sci. 2024; 27:13080.

PMID: 39109269 PMC: 11300292. DOI: 10.3389/jpps.2024.13080.

Paralogue-selective degradation of the lysine acetyltransferase EP300.

Chen X, Crawford M, Xiong Y, Shaik A, Suazo K, Penkalapati M bioRxiv. 2024; .

PMID: 38746397 PMC: 11092752. DOI: 10.1101/2024.05.03.592353.

References

Wilson J, Patel G, Patel C, Brucelle F, Huhn A, Gardberg A . Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor. ACS Med Chem Lett. 2020; 11(6):1324-1329. PMC: 7294707. DOI: 10.1021/acsmedchemlett.0c00155. View

Zhang L, Sheng C, Zhou F, Zhu K, Wang S, Liu Q . CBP/p300 HAT maintains the gene network critical for β cell identity and functional maturity. Cell Death Dis. 2021; 12(5):476. PMC: 8116341. DOI: 10.1038/s41419-021-03761-1. View

Hornbeck P, Zhang B, Murray B, Kornhauser J, Latham V, Skrzypek E . PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 2014; 43(Database issue):D512-20. PMC: 4383998. DOI: 10.1093/nar/gku1267. View

Leaver-Fay A, Tyka M, Lewis S, Lange O, Thompson J, Jacak R . ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol. 2010; 487:545-74. PMC: 4083816. DOI: 10.1016/B978-0-12-381270-4.00019-6. View

Weinert B, Narita T, Satpathy S, Srinivasan B, Hansen B, Scholz C . Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 Acetylome. Cell. 2018; 174(1):231-244.e12. PMC: 6078418. DOI: 10.1016/j.cell.2018.04.033. View

Li X, Liu S, Li X, Li X . YEATS Domains as Novel Epigenetic Readers: Structures, Functions, and Inhibitor Development. ACS Chem Biol. 2022; 18(4):994-1013. DOI: 10.1021/acschembio.1c00945. View

Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert J, Barsyte-Lovejoy D . Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012; 149(1):214-31. PMC: 3326523. DOI: 10.1016/j.cell.2012.02.013. View

Huo S, Liu X, Zhang S, Lyu Z, Zhang J, Wang Y . p300/CBP inhibitor A-485 inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. Int Immunopharmacol. 2021; 94:107458. DOI: 10.1016/j.intimp.2021.107458. View

Durbin A, Wang T, Wimalasena V, Zimmerman M, Li D, Dharia N . EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma. Cancer Discov. 2021; 12(3):730-751. PMC: 8904277. DOI: 10.1158/2159-8290.CD-21-0385. View

10.

Zhou X, Li X, Liao L, Han J, Huang J, Li J . P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib. Acta Pharmacol Sin. 2021; 43(2):457-469. PMC: 8791947. DOI: 10.1038/s41401-021-00643-2. View

11.

Man N, Mas G, Karl D, Sun J, Liu F, Yang Q . p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia. JCI Insight. 2021; 6(19). PMC: 8525640. DOI: 10.1172/jci.insight.138478. View

12.

Lau O, Kundu T, Soccio R, Ait-Si-Ali S, Khalil E, Vassilev A . HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell. 2000; 5(3):589-95. DOI: 10.1016/s1097-2765(00)80452-9. View

13.

Zhang X, Zegar T, Lucas A, Morrison-Smith C, Knox T, French C . Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma. Oncogene. 2020; 39(24):4770-4779. PMC: 7286816. DOI: 10.1038/s41388-020-1301-9. View

14.

Koutelou E, Farria A, Dent S . Complex functions of Gcn5 and Pcaf in development and disease. Biochim Biophys Acta Gene Regul Mech. 2020; 1864(2):194609. PMC: 7854485. DOI: 10.1016/j.bbagrm.2020.194609. View

15.

Hogg S, Motorna O, Cluse L, Johanson T, Coughlan H, Raviram R . Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. Mol Cell. 2021; 81(10):2183-2200.e13. PMC: 8183601. DOI: 10.1016/j.molcel.2021.04.015. View

16.

Tottone L, Zhdanovskaya N, Carmona Pestana A, Zampieri M, Simeoni F, Lazzari S . Histone Modifications Drive Aberrant Notch3 Expression/Activity and Growth in T-ALL. Front Oncol. 2019; 9:198. PMC: 6456714. DOI: 10.3389/fonc.2019.00198. View

17.

Qu K, Chen K, Wang H, Li X, Chen Z . Structure of the NuA4 acetyltransferase complex bound to the nucleosome. Nature. 2022; 610(7932):569-574. DOI: 10.1038/s41586-022-05303-x. View

18.

Baell J, Leaver D, Hermans S, Kelly G, Brennan M, Downer N . Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. Nature. 2018; 560(7717):253-257. DOI: 10.1038/s41586-018-0387-5. View

19.

Narita T, Higashijima Y, Kilic S, Liebner T, Walter J, Choudhary C . Acetylation of histone H2B marks active enhancers and predicts CBP/p300 target genes. Nat Genet. 2023; 55(4):679-692. PMC: 10101849. DOI: 10.1038/s41588-023-01348-4. View

20.

Ogiwara H, Sasaki M, Mitachi T, Oike T, Higuchi S, Tominaga Y . Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression. Cancer Discov. 2015; 6(4):430-45. DOI: 10.1158/2159-8290.CD-15-0754. View